Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy.

Jaggi, Damian; Nagamany, Thanoosha; Ebneter, Andreas; Munk, Marion; Wolf, Sebastian; Zinkernagel, Martin (2020). Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy. The British journal of ophthalmology BMJ Publishing Group 10.1136/bjophthalmol-2020-316514

bjophthalmol-2020-316514.full.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (465kB) | Preview

AIM: To report long-term outcomes on best-corrected visual acuity (BCVA) and treatment intervals with a treat-and-extend (T&E) regimen in patients with neovascular age-related macular degeneration (nAMD).

METHODS: This observational study included treatment-naïve patients with nAMD, treated with aflibercept. A specific T&E protocol without a loading phase and predefined exit criteria was administered. After reaching predefined 'exit-criteria', the treatment period was complete, and patients were observed three monthly.

RESULTS: Eighty-two patients with a follow-up period of ≥2 years were included. BCVA (mean±SD, ETDRS letters) increased from 51.9±25.2 at baseline to 63.7±17.7 (p<0.0001) at 1 year, 61.7±18.5 (p<0.0001) at 2 years, 62.4±19.5 (p<0.0001, n=61) at 3 years and remained insignificantly higher than baseline at 4 years at 58.5±24.3 (p=0.22). Central subfield thickness (mean±SD, μm) decreased significantly from 387.5±107.6 (p<0.0001) at baseline to 291.9±65.5 (p<0.0001) at 1 year, and remained significantly lower until 4 years at 289.0±59.4 (p<0.0001). Treatment intervals (mean±SD, weeks) could be extended up to 9.3±3.1 weeks at 1 year and remained at 11.2±3.5 weeks at 4 years. Twenty-nine (35%) patients reached exit criteria and continued with three monthly observation only.

CONCLUSIONS: After 4 years of treatment, initial vision gains were maintained with a reasonable treatment burden, even without an initial loading phase. Our results on functional outcomes are comparable with large controlled studies.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Jaggi, Damian; Ebneter, Andreas; Munk, Marion; Wolf, Sebastian and Zinkernagel, Martin Sebastian


600 Technology > 610 Medicine & health




BMJ Publishing Group




Andreas Ebneter

Date Deposited:

29 Dec 2020 08:30

Last Modified:

10 Mar 2021 20:06

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Neovascularisation Retina Vitreous




Actions (login required)

Edit item Edit item
Provide Feedback